Testosterone Replacement Therapy in Men With Prostate Cancer on Active Surveillance: A Systematic Review of Oncological Safety
Andrology · 14.07.2026
DOI: 10.1111/andr.70313 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Andrology, online erschienen am 14.07.2026. Verfasst von Mohammed Aly und 8 weiteren Autor:innen. Beteiligte Einrichtung: NHS Forth Valley, Larbert, UK. Die Arbeit nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Up to 20% of men on active surveillance (AS) for prostate cancer (PCa) have symptomatic hypogonadism; the oncological safety of testosterone replacement therapy (TRT) in this population is uncertain.
Objectives
To systematically evaluate the oncological safety of TRT in men with histologically confirmed PCa managed by AS. Materials and Methods PubMed, Embase, and CENTRAL were searched up to January 2026 (PRISMA 2020). Eligible studies enrolled men with PCa on AS receiving TRT for ≥ 12 months. Primary outcomes were biopsy progression, treatment conversion, metastasis, and PCa‐specific mortality. Risk of bias was assessed using a modified Newcastle–Ottawa Scale.
Results
Seven observational studies (2011–2025; 295 TRT‐treated men; 6826 non‐TRT AS comparators; follow‐up 2.3–6.1 years) were included. No PCa‐specific deaths or metastatic events were reported among TRT recipients. The single controlled biopsy comparison showed comparable Gleason upgrading (10.7% TRT vs. 9.4% comparators; p = 0.732) and no significant difference in biopsy progression (32.1% vs. 44.7%; p = 0.280). The largest population‐based study reported lower treatment conversion versus non‐TRT AS controls (16.8% vs. 21.9%; adjusted HR 0.66, 95% CI 0.46–0.97), most plausibly reflecting selection bias. PSA remained stable despite two‐ to threefold testosterone increases and correlated poorly with histological progression.
Discussion
Short‐ to intermediate‐term observational evidence does not demonstrate increased oncological risk with TRT in the predominantly low‐risk populations studied. However, retrospective design, small samples, group imbalance, heterogeneous surveillance, and short follow‐up relative to AS natural history substantially limit these findings.
Conclusion
TRT may be cautiously considered in selected hypogonadal men on AS through shared decision‐making; prospective studies with standardised surveillance and extended follow‐up are required before broader recommendations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- NHS Forth Valley, Larbert, UK.
- NHS Fife, Dunfermline, UK.
- Western General Hospital, Edinburgh, UK.
- Queen Elizabeth University Hospital, Glasgow, UK.
ORCID-Profile: Mohammed Aly
Zitieren
APA
Aly, M., Alshunaigat, N., Habana, Y., Elsayed, Y., Jaafari, F. A., Chapman, A., Bajis, R., Bhatt, J., & Amer, T. (2026). Testosterone Replacement Therapy in Men With Prostate Cancer on Active Surveillance: A Systematic Review of Oncological Safety. Andrology. https://doi.org/10.1111/andr.70313
Vancouver
Aly M, Alshunaigat N, Habana Y, Elsayed Y, Jaafari FA, Chapman A, et al. Testosterone Replacement Therapy in Men With Prostate Cancer on Active Surveillance: A Systematic Review of Oncological Safety. Andrology. 2026. doi:10.1111/andr.70313
BibTeX
@article{Aly2026,
author = {Aly, Mohammed and Alshunaigat, Nadeem and Habana, Yahia and Elsayed, Yasser and Jaafari, Feras Al and Chapman, Alex and Bajis, Rami and Bhatt, Jaimin and Amer, Tarik},
title = {Testosterone Replacement Therapy in Men With Prostate Cancer on Active Surveillance: A Systematic Review of Oncological Safety},
journal = {Andrology},
year = {2026},
doi = {10.1111/andr.70313}
}
EUVIMED